Advertisement
Organisation › Details
ProfoundBio US Co.
ProfoundBio is a clinical-stage biotechnology company focused on the development of novel antibody-based therapeutics for patients with cancer. Built on internally developed, innovative, and proprietary technology platforms, ProfoundBio has developed a pipeline consisting of multiple ADC drug candidates targeting solid tumors and hematological malignancies. The company's disclosed development pipeline consists of rinatabart sesutecan (Rina-S; PRO1184), an ADC targeting FRa; PRO1160, an ADC targeting CD70; PRO1107, an ADC targeting PTK7; and PRO1286, a bispecific ADC targeting EGFR and cMET. ProfoundBio is headquartered in Seattle, Washington with an R&D center of innovation in Suzhou, China. *
Start | 2024-04-03 acq.announeced | |
Group | Genmab (Group) | |
Industry | antibody-drug conjugate (ADC) | |
Industry 2 | antibody-drug conjugates (ADC) technology | |
Person | Zhao, Baiteng (ProfoundBio 202107 CEO) | |
Region | Seattle, WA | |
Country | United States (USA) | |
Street | 401 Terry Avenue N | |
City | 98109 Seattle, WA | |
Address record changed: 2024-04-03 | ||
Basic data | Employees | n. a. |
* Document for »About Section«: Genmab A/S. (4/3/24). "Press Release: Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio". Copenhagen & Seattle, WA. | ||
Record changed: 2024-04-03 |
Advertisement
More documents for Genmab (Group)
- [1] Genmab A/S. (4/3/24). "Press Release: Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio". Copenhagen & Seattle, WA....
- [2] Argenx SE. (4/17/23). "Press Release: Argenx and Genmab Enter Partnership to Advance Antibody Therapies in Immunology and Oncology". Amsterdam....
- [3] BioNTech SE. (8/5/22). "Press Release: BioNTech and Genmab Expand Global Strategic Collaboration to Develop and Commercialize Novel Immunotherapy Candidates". Mainz & Copenhagen....
- [4] Synaffix B.V.. (7/22/21). "Press Release: Synaffix Announces Deal with ProfoundBio Worth up to $246 Million Providing Access to Multiple Novel Linker-Payload Technologies". Amsterdam....
- [5] Genmab A/S. (11/24/20). "Press Release: Genmab Announces Enapotamab Vedotin Update. Genmab Will Not Advance the Development of Enapotamab Vedotin". Copenhagen....
- [6] Bioqube Ventures. (6/10/20). "Press Release: Bioqube Ventures Launches Bioqube Factory Fund I". Hasselt/Brussels....
- [7] Genmab A/S. (6/10/20). "Press Release: Genmab and AbbVie Announce Broad Oncology Collaboration". Copenhagen & North Chicago, IL....
- [8] Rentschler Biopharma SE. (5/27/20). "Press Release: Rentschler Biopharma Extends Collaboration with Genmab to U.S. Facility". Laupheim & Milford, MA....
- [9] CureVac AG. (3/11/20). "Press Release: Company Founder Ingmar Hoerr Succeeds Daniel Menichella as CEO of CureVac AG". Tübingen & Boston, MA....
- [10] Genmab A/S. (12/19/19). "Press Release: Genmab and CureVac Enter Strategic Partnership to Develop mRNA-based Antibody Therapeutics". Copenhagen & Tübingen....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top